Tuesday, April 1, 2025
4/1/2025
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo - PROJECT SUMMARY/ABSTRACT The RAS family comprised of KRAS, NRAS, and HRAS are the most commonly mutated oncogenes in human cancer. Despite there being over 50 possible oncogenic RAS mutations, each cancer type has a specific and often unique subset of these mutations. As RAS mutations typically occur early during tumorigenesis, if not being the initiating mutation, these mutational patterns reflect fundamental biology underlying the process of tumor initiation. Elucidating the mechanisms giving rise to RAS mutation patterns would therefore address a foundational question in cancer biology- how cancer originates. Given this, the most informative approach to interrogate these patterns is to study RAS mutations when they 1) first occur in 2) normal cells in an 3) in vivo setting. Trying to backtrack to catch that one random mutagenic event in one gene from one cell that initiates cancer decades before manifesting as a disease is challenging in humans. There are, however, two murine model systems that allow an initiating RAS mutation to be precisely defined, and hence are amenable to studying RAS mutation patterns. One, carcinogenesis, which is particularly well suited to interrogate how the mutagenic process gives rise to RAS mutation patterns. Two, genetic activation of mutant alleles in a spatially and temporally restricted fashion, which is ideal to study the response of defined Ras mutations in normal cells. We thus propose to capitalize on the individual strengths of these two different models to elucidate the mechanisms by which RAS mutation patterns are laid down in normal cells at the very onset of tumorigenesis in vivo. Specifically, in aim 1 we will determine how tumors arise by a specific Ras mutation by monitoring mutagenesis immediately after carcinogen exposure and thereafter in genetic backgrounds that alter RAS mutation patterns. In aim 2 we will determine the signaling and cellular responses of different normal cells upon genetic induction of different oncogenic Ras mutants. Completion of this proposal will thus elucidate the principles underlying the selection for specific RAS mutations in human cancers, and more broadly, how cancers originate, which has clinical implications for early detection and prevention.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).